RSS Feed
Tags
adaptive trials advertising advisory committees best practices biologics biosimilar biotech BLA cancer Cato BioVentures Cato Research CBER CDER CDRH clinical trials CMC conference DDMAC DIA drug development eCTD efficacy FDA GlobalSubmit guest post guidance IND inspections medical devices NDA NIH nonclinical research oncology outsourcing personalized medicine postmarketing protocol safety slides Social Media statistical analysis transparency venture capital warning letters webinarCategories
Archives
Links
Follow us on Twitter!
- Featured yesterday at Fierce Biotech IT - Cato lists five keys to success in adaptive trials http://bit.ly/aHry0A about 17 hours ago from TweetDeck
- RT @reuters: "Outgunned FDA tries to get tough with drug ads" http://bit.ly/btorHn 08:45:47 PM September 07, 2010 from web
- @MicroConstants Thanks for retweeting! 07:27:43 PM September 07, 2010 from TweetDeckin reply to MicroConstants
- New blog post: August 2010 FDA Guidances - http://ask-cato.com/mg 02:50:26 PM September 07, 2010 from WordTwit Plugin
Tag Archives: cancer
Cato at the Cancer Vaccines Meeting
This week, Cato Research is attending the Cancer Vaccines meeting in Cambridge, MA on 29 and 30 June. The conference is the first meeting dedicated to progressing cancer vaccines to market and will feature 21 of the world’s leading experts … Continue reading
Posted in Conferences and Meetings
Tagged cancer, Chemotherapy, clinical trials, immune system, monoclonal antibody therapy, pancreatic cancer, vaccines
Comments Off
LIPID MAPS 2010 Annual Meeting
This is a guest post by Kathy Grako, Ph.D., PMP. Kathy is a Clinical Strategy Scientist in Cato Research’s San Diego, CA office. The LIPID Metabolites and Pathway Strategy (MAPS) Annual Meeting was held at UCSD in La Jolla, CA … Continue reading
Posted in Conferences and Meetings, Guest Posts
Tagged Alzheimer’s, arthritis, atherosclerosis, cancer, diabetes, Duke, glucose, inflammation, inflammatory, insulin, lipid, LIPID MAPS, macrophages, Nobel Prize, obesity, stroke, UCSD, UNC, Vanderbilt
Comments Off
Approval of Therapeutic Cancer Vaccines
This is a guest post by Laura DiMichele, Ph.D., R.A.C. Laura is a Clinical Strategy Scientist at Cato Research. Last month, Dendreon was granted approval for Provenge®, the first cell based cancer vaccine for treatment of asymptomatic or minimally symptomatic metastatic … Continue reading
Posted in FDA, Guest Posts, Industry News, Publications
Tagged biomedical, cancer, Cancer Advances, cancer vaccine, Cato BioVentures, clinical benefit, clinical development, Dendreon, drug development, gastric cancer, gastrointestinal cancers, immune system, immunomodulators, Journal for Clinical Studies, monoclonal antibody therapy, pancreatic cancer, Provenge, serum-derived polyclonal treatment, targeted therapeutics, tumors
1 Comment
